XORTX Therapeutics Inc.
XRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729214
No open-market purchases or sales by XORTX Therapeutics Inc. insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $92.8K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding XORTX Therapeutics Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 3 | 6 | +3 |
| Shares | 15.3K | 40.4K | +25.1K (+163.9%) |
| Value | $6.25K | $92.8K | +$86.6K (+1,386.4%) |
New holders (4)
Institutions that held XORTX Therapeutics Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 23,116 | $52.5K | 0.00% |
| StoneX Group Inc. | 16,369 | $37.9K | 0.00% |
| Royal Bank of Canada | 732 | $2.00K | 0.00% |
| National Bank of Canada | 162 | $329 | 0.00% |
Sold out (1)
Institutions that held XORTX Therapeutics Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Kingsview Wealth Management, LLC | 15,000 | $6.13K |